Financing ·
RedHill Bioharma Ltd. entered into a Securities Purchase Agreement on June 18, 2026, for a private placement of…
RDHLRedHill Biopharma Ltd.
RedHill Bioharma Ltd. entered into a Securities Purchase Agreement on June 18, 2026, for a private placement of 8,571,429 ADSs and accompanying warrants. The offering expected to raise approximately $6 million in gross proceeds, with potential additional proceeds of $13.4 million from warrant exercises. H.C. Wainwright & Co. is acting as the exclusive placement agent. RedHill Bioharma Ltd. is a biopharmaceutical company focused on developing and commercializing gastrointestinal and infectious disease treatments.